LOTEMAX® Ointment has ~82% unrestricted managed care access on commercial insurance plans*

*MMIT data 2018.

 

PATIENT SAVINGS

Most eligible commercially insured patients pay no more than $35 co-pay†

Most eligible commercially insured patients PAY NO MORE THAN $35† co-pay for 1st prescription and eligible refills. Discounted pricing is also available for eligible uninsured patients.†

To help eligible patients save, visit the link below to access web coupons or contact your sales representative to provide printed coupons in-office.

Access Patient Commercial Coupon

Ensure your patients activate their coupon

ACTIVATE: To activate the print coupon, call 1-866-693-4880.

To activate the web coupon, visit www.bauschaccessprogram.com and follow the instructions.

Bausch + Lomb has aligned with Walgreens to stock product and help eligible patients redeem special prescription savings on LOTEMAX® Ointment.

Co-pay for eligible patients

images

If you have any questions regarding the program, please call 1-866-693-4880.

†Terms and conditions apply. Please see www.bauschaccessprogram.com for eligible criteria and terms and conditions.

Indication

LOTEMAX® Ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Important Safety Information

  • LOTEMAX® Ointment, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation and may delay healing and increase the incidence of bleb formation after cataract surgery. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification.
  • Corticosteroids may increase the hazard of secondary ocular infections. If pain, redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Fungal culture should be taken when appropriate.
  • Patients should not wear contact lenses during their course of therapy with LOTEMAX® Ointment. LOTEMAX® should not be used in children following ocular surgery as it may interfere with amblyopia treatment. LOTEMAX® is not indicated for intraocular administration.
  • The most common ocular adverse event, reported in approximately 25% of subjects in clinical studies, is anterior chamber inflammation. Other common adverse events, with an incidence of 4-5%, are conjunctival hyperemia, corneal edema, and eye pain. Many of these events may have been the consequence of the surgical procedure.

Click here for full Prescribing Information for LOTEMAX® Ointment.

logo
logo

©Bausch & Lomb Incorporated. All rights reserved. LEO.0027.USA.18

Indication and Important Safety Information
SHOW MORE

Indication

LOTEMAX® Ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Important Safety Information

  • LOTEMAX® Ointment, as with other ophthalmic corticosteroids, is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation and may delay healing and increase the incidence of bleb formation after cataract surgery. The initial prescription and renewal of the medication order beyond 14 days should be made by a physician only after examination of the patient with the aid of magnification.
  • Corticosteroids may increase the hazard of secondary ocular infections. If pain, redness, itching or inflammation becomes aggravated, the patient should be advised to consult a physician. If signs and symptoms fail to improve after 2 days, the patient should be reevaluated. Fungal culture should be taken when appropriate.
  • Patients should not wear contact lenses during their course of therapy with LOTEMAX® Ointment. LOTEMAX® should not be used in children following ocular surgery as it may interfere with amblyopia treatment. LOTEMAX® is not indicated for intraocular administration.
  • The most common ocular adverse event, reported in approximately 25% of subjects in clinical studies, is anterior chamber inflammation. Other common adverse events, with an incidence of 4-5%, are conjunctival hyperemia, corneal edema, and eye pain. Many of these events may have been the consequence of the surgical procedure.

Click here for full Prescribing Information for LOTEMAX® Ointment.

References: 1. LOTEMAX Ointment [package insert]. Tampa, FL: Bausch & Lomb Incorporated. 2. Drugs@FDA.com website. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed May 30, 2018.

Click here for IMPORTANT SAFETY INFORMATION